ArticleJournal of managed care & specialty pharmacy2019
Value-Based Insurance Design: Current Evidence and Future Directions.
Article in Journal of managed care & specialty pharmacy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Do subsidies reach the sick? Implementation challenges and equity implications of pharmaceutical subsidy reform in Iran: a qualitative study.International journal for equity in health · 2026Article
- Advancing the conversation: 30 years of scholarship in managed care pharmacy.Journal of managed care & specialty pharmacy · 2025Article
- Value-Based Healthcare in Cardiology: How to Integrate a more Comprehensive View into Medical Decision-Making?Arquivos brasileiros de cardiologia · 2025Review
- Association of Participation in a Value-Based Insurance Design Program With Health Care Spending and Utilization.JAMA network open · 2023Article
- Availability of Cost-effectiveness Studies for Drugs With High Medicare Part D Expenditures.JAMA network open · 2021Article
- Letter--Assessing the Effectiveness of V-BID Implementations.Journal of managed care & specialty pharmacy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Value-based insurance design (VBID) is an approach to designing insurance to align the use of health care services with some notion of value. While there is substantial federal interest in VBID and a growing body of evidence of its effects among populations covered by employer-sponsored plans, much of the focus has been on VBIDs that solely reduce cost sharing for certain treatments. The minority of VBIDs that have identified and increased cost sharing for low-value treatments have produced some promising results. Looking to the future, health plans should continue to develop and benefit from innovations in formulary design and health information technology that distinguishes and incentivizes high-value drugs in a patient-specific manner. DISCLOSURES: No funding contributed to the writing of this article. The author has nothing to disclose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.